Emergent BioSolutions | EBS - Selling And Administration Expenses


Emergent BioSolutions reported $182.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 91.66M 18.01M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Exelixis USD 147.63M 8.03M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.89B 219M Jun/2026
Moderna USD 216M 43M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sanofi EUR 2.63B 307M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
United Therapeutics USD 206.7M 50.1M Jun/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024